Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02AIC
|
||||
| Former ID |
DIB004413
|
||||
| Drug Name |
CP-870893
|
||||
| Synonyms |
Fully human CD40 agonist antibody, Pfizer; CD40 ligand (cancer), Pfizer
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [523006] | ||
| Company |
Pfizer Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | [532263], [532466] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| NF-kappa B signaling pathway | |||||
| Cell adhesion molecules (CAMs) | |||||
| T cell receptor signaling pathway | |||||
| Intestinal immune network for IgA production | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Asthma | |||||
| Autoimmune thyroid disease | |||||
| Systemic lupus erythematosus | |||||
| Allograft rejection | |||||
| Primary immunodeficiency | |||||
| Viral myocarditis | |||||
| References | |||||
| Ref 532263 | Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013 Jan 1;2(1):e23033. | ||||
| Ref 532466 | A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013 Nov 15;19(22):6286-95. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.